Bortezomib Unknown Status Phase 3 Trials for Extramedullary Plasmacytoma Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02336386CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma